According to GlobalData, Phase II drugs for Pheochromocytoma have a 33% phase transition success ... advanced melanoma, non-small cell lung cancer, esophageal cancer, small cell lung cancer (SCLC), ...
Zacks.com on MSN1d
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & MoreSanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...
non-small cell lung cancer, pheochromocytoma and paraganglioma (PPGL), small cell lung cancer, pancreatic cancer, ovarian cancer, metastatic ovarian cancer and gallbladder cancer, soft tissue sarcoma ...
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
Allison Ciaccio had a respiratory illness that wouldn't go away. Repeated follow-ups found Stage I lung cancer.
8don MSN
Yovana Portillo felt stunned that she had lung cancer because she never smoked. But she hopes people realize that lung cancer ...
From 1990 to 2019, global lung cancer mortality rates related to tobacco have gone down, whereas rates related to ambient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback